Synergy between an antiangiogenic integrin αvantagonist and an antibody–cytokine fusion protein eradicates spontaneous tumor metastases
Authors:
- 16 February 1999
- journal article
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 96 (4) , 1591-1596
Abstract
The suppression and eradication of primary tumors and distant metastases is a major goal of alternative treatment strategies for cancer, such as inhibition of angiogenesis and targeted immunotherapy. We report here a synergy between two novel monotherapies directed against vascular and tumor compartments, respectively, a tumor vasculature-specific antiangiogenic integrin alphav antagonist and tumor-specific antibody-interleukin 2 (IL-2) fusion proteins. Simultaneous and sequential combination of these monotherapies effectively eradicated spontaneous liver metastases in a poorly immunogenic syngeneic model of neuroblastoma. This was in contrast to controls subjected to monotherapies with either an antiangiogenic integrin alphav antagonist or antibody-IL-2 fusion proteins, which were only partially effective at the dose levels applied. Furthermore, simultaneous treatments with the integrin alphav antagonist and tumor-specific antibody-IL-2 fusion proteins induced dramatic primary tumor regressions in three syngeneic murine tumor models, i.e., melanoma, colon carcinoma, and neuroblastoma. However, each agent used as monotherapy induced only a delay in tumor growth. A mechanism for this synergism was suggested because the antitumor response was accompanied by a simultaneous 50% reduction in tumor vessel density and a 5-fold increase in inflammatory cells in the tumor microenvironment. Subsequently, tumor necrosis was demonstrated only in animals receiving the combination therapy, but not when each agent was applied as monotherapy. The results suggest that these synergistic treatment modalities may provide a novel and effective tool for future therapies of metastatic cancer.Keywords
This publication has 22 references indexed in Scilit:
- T cell-mediated eradication of murine metastatic melanoma induced by targeted interleukin 2 therapy.Journal of Experimental Medicine, 1996
- Definition of Two Angiogenic Pathways by Distinct α v IntegrinsScience, 1995
- Antiintegrin alpha v beta 3 blocks human breast cancer growth and angiogenesis in human skin.Journal of Clinical Investigation, 1995
- Dormancy of micrometastases: Balanced proliferation and apoptosis in the presence of angiogenesis suppressionNature Medicine, 1995
- A phase I study of human/mouse chimeric antiganglioside GD2 antibody ch14.18 in patients with neuroblastomaEuropean Journal of Cancer, 1995
- Integrin αvβ3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vesselsCell, 1994
- Angiostatin: A novel angiogenesis inhibitor that mediates the suppression of metastases by a lewis lung carcinomaCell, 1994
- Randomised trial of monoclonal antibody for adjuvant therapy of resected Dukes' C colorectal carcinomaThe Lancet, 1994
- Requirement of Vascular Integrin α v β 3 for AngiogenesisScience, 1994
- HUMAN MONOCLONAL ANTIBODY TO GANGLIOSIDE GM2 FOR MELANOMA TREATMENTThe Lancet, 1989